NCT04388852View on ClinicalTrials.gov

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Prostate CarcinomaMetastatic Urothelial CarcinomaStage IV Prostate Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
Interventions
BIOLOGICAL

Ipilimumab

Given IV

DRUG

Valemetostat

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER